5/31
08:43 am
mirm
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older [Yahoo! Finance]
Medium
Report
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older [Yahoo! Finance]
5/31
08:30 am
mirm
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
Medium
Report
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
5/30
07:59 am
mirm
Shareholders May Be More Conservative With Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) CEO Compensation For Now [Yahoo! Finance]
Low
Report
Shareholders May Be More Conservative With Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) CEO Compensation For Now [Yahoo! Finance]
5/29
08:34 am
mirm
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress [Yahoo! Finance]
Low
Report
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress [Yahoo! Finance]
5/29
08:30 am
mirm
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
Low
Report
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
5/28
11:43 am
mirm
Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns [Yahoo! Finance]
Low
Report
Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns [Yahoo! Finance]
5/28
06:58 am
mirm
When Will Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Become Profitable? [Yahoo! Finance]
Low
Report
When Will Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Become Profitable? [Yahoo! Finance]
5/18
07:11 am
mirm
Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting [Yahoo! Finance]
5/18
07:00 am
mirm
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
Low
Report
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
5/10
07:30 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/10
01:39 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at Morgan Stanley from $57.00 to $53.00. They now have an "overweight" rating on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at Morgan Stanley from $57.00 to $53.00. They now have an "overweight" rating on the stock.
5/9
03:40 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at JMP Securities from $72.00 to $66.00. They now have a "market outperform" rating on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at JMP Securities from $72.00 to $66.00. They now have a "market outperform" rating on the stock.
5/9
02:05 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc. from $37.00 to $38.00. They now have a "buy" rating on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc. from $37.00 to $38.00. They now have a "buy" rating on the stock.
5/9
01:47 pm
mirm
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
Low
Report
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
5/9
11:09 am
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $40.00 price target on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $40.00 price target on the stock.
5/9
08:17 am
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $58.00 price target on the stock.
Medium
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $58.00 price target on the stock.
5/8
04:02 pm
mirm
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
5/7
04:10 pm
mirm
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
Medium
Report
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
5/7
08:30 am
mirm
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
Low
Report
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
5/1
04:18 pm
mirm
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 [Yahoo! Finance]
5/1
04:10 pm
mirm
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Low
Report
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
4/26
09:45 am
mirm
Liver Cirrhosis Pipeline Insights, 2024: Featuring 45+ Companies and 50+ Pipeline Drugs, Including Elafibranor (Ipsen), Volixibat (Mirum Pharmaceuticals), and PVT201 (Parvus Therapeutics) [Yahoo! Finance]
Low
Report
Liver Cirrhosis Pipeline Insights, 2024: Featuring 45+ Companies and 50+ Pipeline Drugs, Including Elafibranor (Ipsen), Volixibat (Mirum Pharmaceuticals), and PVT201 (Parvus Therapeutics) [Yahoo! Finance]
4/25
11:44 am
mirm
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release [Yahoo! Finance]
Medium
Report
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release [Yahoo! Finance]
4/22
04:06 pm
mirm
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value [Seeking Alpha]
Low
Report
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value [Seeking Alpha]
4/17
03:01 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $48.00 price target on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $48.00 price target on the stock.